Bottom line
What is EPIBX's expense ratio?
EPIBX's expense ratio is 1.17%, or about $117 a year on every $10,000 invested. That is more expensive than 74% of global bond funds we track (median 0.89%). This share class also charges a front-end sales load of up to 4.5%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Mar 4, 2026
EPIBX fee table
| Net expense ratio | 1.17% |
|---|---|
| Gross expense ratio | 1.47% |
| Management fee | 0.6% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.6% |
| Acquired fund fees | 0.02% |
| Fee waiver / reimbursement | -0.3% |
| Max front-end sales load | 4.5% |
| Max deferred sales charge | 0% |
| Redemption fee | -2% |
Source: Fund prospectus fee table, filed Mar 4, 2026
What EPIBX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| EPIBX | $564 | $866 | $1,189 | $2,104 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.17% expense ratio costs roughly $63,800 in lost growth, versus about $49,800 for the median global bond fund (0.89%).